@article {HATA475, author = {AKITO HATA and NOBUYUKI KATAKAMI and SHIGEKI NANJO and CHIYUKI OKUDA and REIKO KAJI and YUKIHIRO IMAI}, title = {Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures}, volume = {31}, number = {3}, pages = {475--479}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: The aim of the present study was to compare successful rate, failure reasons, and complications among procedures of histological rebiopsy. Patients and Methods: We retrospectively reviewed medical records of histologically rebiopsied cases with non-small cell lung cancer. Results: One hundred and eleven histological rebiopsies were performed in: 86 (77\%) lung; 11 (10\%) lymph node; 5 (5\%) pleura; 4 (4\%) liver; 2 (2\%) muscle; 2 (2\%) adrenal gland; and 1 (1\%) rib. Successful rate by computed tomography-guided biopsy (CTGB), transbronchial biopsy (TBB), and ultrasound-guided biopsy were 86\% (48/56), 90\% (28/31), and 100\% (24/24), respectively. Reasons for rebiopsy failure by CTGB were no/insufficient malignant cells (n=5) and pneumothorax (n=3), and those by TBB were no/insufficient malignant cells (n=2) and bleeding (n=1). Severe complications (>=grade 3): one grade 3 pneumothorax and one grade 4 air embolization were observed in two (2\%, 2/111) cases receiving CTGB. Conclusion: Rebiopsy of histological samples can be highly successful and feasible by optimal procedural selection.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/31/3/475}, eprint = {https://iv.iiarjournals.org/content/31/3/475.full.pdf}, journal = {In Vivo} }